Feb 22,2024

Ciba Health Taps Instacart to Help Enable Improved Access to Nutritious Foods Through Chronic Disease Care Platform

Ciba Health, a global chronic disease prevention and reversal integrated care platform, announced a new collaboration with Instacart, the leading grocery technology company in North America, to use Instacart Health technology to support Ciba Health's digital integrated healthcare solutions, and increase access to essential nutritious food for populations managing chronic and metabolic diseases, including type 2 diabetes, obesity, auto-immune conditions, digestive disorders, hypertension, and more. The collaboration with Instacart will offer participants the convenience of online  grocery shopping and delivery through Ciba Health programs, offering a more streamlined experience that helps participants take action on Ciba Health's expert nutrition advice.

COLLABORATION PARTNERSHIP

#product & service

#virtual care

#coaching

View Analyst & Ambassador Comments
Go to original news
Feb 21,2024

Tandem Diabetes Care Announces Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance

Tandem Diabetes Care reported its financial results for the quarter and year ended December 31, 2023 and provided its financial guidance for the year ending December 31, 2024. Key highlights include a 7% increase in the worldwide installed base, reaching approximately 452,000 in-warranty customers. Tandem Mobi, the world's smallest durable Automated Insulin Delivery (AID) System, was successfully launched in the United States. Notably, the company achieved a first-to-market launch with multiple next-generation continuous glucose monitoring sensor integrations. The introduction of Tandem Source, a new diabetes management platform, further solidifies Tandem's commitment to enhancing customer and healthcare provider experiences. As of December 31, 2023, Tandem Diabetes Care reported $467.9 million in cash, cash equivalents, and short-term investments. These achievements, coupled with the successful introduction of four new products in the United States, position Tandem for a promising 2024.

View Analyst & Ambassador Comments
Go to original news
Feb 19,2024

Tailor fit digital health tech to the elderly's needs: study

A recent South Korean study surveyed 505 respondents aged 65 and older, revealing differences in healthcare app and wearable device usage between healthy and frail seniors. While 63% were smartphone users, a quarter used healthcare apps, with a higher prevalence among healthy seniors. Frail seniors relied on apps for healthcare information and guidance. Challenges were noted in app installation for 63% of respondents. The study emphasized the importance of developing technologies tailored to the unique needs of frail seniors to enhance their engagement with digital health tools.

View Analyst & Ambassador Comments
Go to original news
Feb 22,2024 TOP STORY

New Challenger Onboard? Syai Health Brings the New Fashion to CGM Experience & Chronic Disease Management

Singapore-based biotech company, Syai Health, abbreviated for "Sychronise + AI", secured significant funding from leading investors like AstraZeneca plc and Xiaomi Corporation for its in-house developed AI-empowered medical devices. Syai Health is prepared to broaden the horizon and reshape the CGM experience with its user-centric product lineup empowered by AI integration. Syai's CGM device pairs with a user-friendly app and cloud-based data solutions that allow patients to track, retrieve, and share real-time data or reports with their healthcare providers or families for more comprehensive care.

FUNDING FUNDING ROUND

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 20,2024

Lilly to Participate in Cowen's 44th Annual Health Care Conference

Eli Lilly and Company (NYSE: LLY) will participate in Cowen's 44th Annual Health Care Conference on March 6, 2024. Anat Ashkenazi, executive vice president and chief financial officer, will take part in a fireside chat at 9:10 a.m., Eastern time.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Feb 22,2024

Hedia appoints new CEO

Hedia announced today the appointment of their new CEO Lars Christian Lund. Lars has a strong track record of scaling market leading global MedTech companies. Prior to joining Hedia Lars was Senior Vice President in 3Shape where he was on the senior leadership team with global responsibility for several commercial functions and earlier 5 years at Ambu and 9 years with Unomedical now Convatec Infusion Care.

View Analyst & Ambassador Comments
Go to original news
Feb 21,2024 TOP STORY

Dario acquires Twill creating one of the most comprehensive digital health platform across the most prevalent chronic conditions

DarioHealth announced that it has acquired Twill, Inc., a leader in digital-led care. The combination enables Dario to create one of the most comprehensive digital offerings in the market for chronic conditions, spanning a wide spectrum of health and well-being needs from emotional health to the costliest chronic conditions. The transaction creates immediate scale, with three of the top eight national health plans, multiple Fortune 100 employers and several major pharmaceutical companies as customers. According to DarioHealth's press release, the acquisition of Twill is expected to nearly double pro forma 2023 revenue, and gross margins are expected to reach approximately 80-85% by 2025. 

COLLABORATION MERGERS & ACQUISITION

#product & service

#coaching

View Analyst & Ambassador Comments
Go to original news
Feb 20,2024

Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease

Better Therapeutics announced that the FDA has granted Breakthrough Device Designation for its novel Cognitive Behavioral Therapy (CBT) platform intended to treat adults with metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH. Better Therapeutics earned breakthrough status based on the outcomes of its LivVita clinical study, which successfully met its primary endpoint by reducing liver fat within 90 days, while also achieving key secondary endpoints related to improved liver health without any device-related adverse events. Results of the study were published in Gastro Hep Advances. Besides this, the Company’s CBT platform has already demonstrated clinically meaningful outcomes in type 2 diabetes, leading to the FDA authorization of AspyreRx™ in 2023 as the first prescription digital therapy to deliver CBT as a treatment for T2D.

REGULATORY FDA

#dtx

View Analyst & Ambassador Comments
Go to original news
Feb 13,2024

Omada Health Enhances GLP-1 Care Track to Support Customers Managing Medications and Integrates MSK Support

Omada Health announced an expansion of its GLP-1 companion solution, adding customized partner support for medication eligibility and expanded exercise programming that leverages its musculoskeletal expertise. The enhanced GLP-1 Care Track, designed for the duration of GLP-1 medication use and afterward, will support Omada’s full cardiometabolic suite, which includes prevention, diabetes and hypertension programs. It leverages behavioral support, weight monitoring, nutrition, medication management education, and tailored exercise and movement plans designed by Omada’s physical therapists to optimize muscle mass, and builds on updates to the Omada for Prevention program announced in May 2023. Omada will track the impact during and after medication to demonstrate how the programming helps members maximize weight loss and keep it off.

PRODUCT

#dtx

#coaching

View Analyst & Ambassador Comments
Go to original news
Feb 13,2024

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF LUIS MALAVÉ TO CHAIR OF THE BOARD OF DIRECTORS

Glucotrack, a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes announced that Luis Malavé has been elected as Chairman of its Board of Directors, effective immediately. Mr. Malavé currently serves as President of EOFLOW CO. Ltd., a company listed on the Korea Stock Exchange that has developed a wearable disposable insulin pump. Prior to that, Mr. Malavé was the President and CEO of Palyon Medical, maker of an implantable drug-delivery system that spun out from German medical-technology giant Fresenius SE.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES